Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. Financial performance and product development updates appear positive, with new studies and strategic pricing strategies. However, management's vague responses in the Q&A raise concerns about transparency, particularly regarding ulixacaltamide's review process and essential tremor database updates. This lack of clarity may offset the positives, leading to a neutral sentiment.
Key Financial Performance
Q4 2025 Operating Expenses $97 million, broken down to $77.5 million for R&D and $19.5 million for G&A. This compares to Q4 2024, where total operating expenses were $71.4 million, broken down to $56.3 million for R&D and $15.1 million for G&A. The increase was driven by increased spending in the Cerebrum and Solidus platforms to progress the portfolio of clinical programs.
Full Year 2025 Operating Expenses $326 million compared to $209 million in 2024. The increase was driven by increased spending in the Cerebrum and Solidus platforms to progress the portfolio of clinical programs.
Cash, Equivalents, and Marketable Securities (End of Q4 2025) $926 million compared to $469 million as of December 31, 2024. The increase of $457 million was primarily due to net proceeds from Praxis October 25 follow-on public offering and net proceeds from the at-the-market sales of common stock offset by cash used in operations.
Pro Forma Cash (January 2026) Approximately $1.5 billion, strengthened through proceeds from a public offering in January 2026, which yielded $621 million. This cash is expected to fund operations into 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ulixacaltamide: Positive clinical results in Essential3 program for essential tremor. NDA submitted to FDA. Preparations for commercial launch underway. Estimated market potential of over $10 billion annually.
Relutrigine: NDA submitted for SCN2A and 8A DEEs. Strong clinical results with potential market of $5 billion annually. Prelaunch activities initiated.
Vormatrigine: Phase III studies ongoing for focal epilepsy. Potential market of $4 billion annually. Multiple readouts expected in the next 12-18 months.
Elsunersen: Developed for SCN2A DEE. Simplified trial design approved by FDA. Potential NDA submission next year. Estimated market potential of $1 billion annually.
Essential Tremor Market: Estimated 7 million people in the U.S. with essential tremor, 2 million in immediate need of therapy. Ulixacaltamide positioned to address this unmet need.
Epilepsy Market: Approximately 3 million people in the U.S. with common epilepsies. Vormatrigine and relutrigine targeting significant unmet needs.
Financial Position: Ended 2025 with $926 million in cash, strengthened to $1.5 billion in January 2026. Expected to fund operations into 2028.
Operational Expenses: 2025 operating expenses totaled $326 million, up from $209 million in 2024, driven by increased R&D and pre-commercial activities.
Commercial Transition: Company transitioning to a commercial phase with prelaunch activities for ulixacaltamide and relutrigine.
Pipeline Expansion: Focused on advancing clinical programs and unlocking over $20 billion in opportunities across CNS portfolio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is heavily reliant on FDA approvals for its drugs, including ulixacaltamide, relutrigine, vormatrigine, and elsunersen. Any delays or rejections in the approval process could significantly impact their timelines and financial projections.
Commercialization Challenges: The company is transitioning into a commercial phase, which involves building a commercial organization, hiring key personnel, and launching medical education campaigns. Any missteps in these activities could hinder the successful launch of their drugs.
Financial Risks: Operating expenses have increased significantly, with a notable rise in R&D and G&A costs. The company is also planning for a substantial increase in spending for commercial launch activities, which could strain financial resources if revenues do not materialize as expected.
Market Risks: The company is entering highly competitive markets for CNS disorders, epilepsy, and essential tremor. The success of their drugs depends on their ability to demonstrate superior efficacy and safety compared to existing treatments.
Clinical Development Risks: The company has multiple ongoing clinical trials, including POWER1, POWER2, and EMBRAVE3. Any negative results or delays in these trials could impact their ability to submit NDAs and achieve market entry.
Supply Chain Risks: The company is building inventory for the expected launch of relutrigine and other drugs. Any disruptions in the supply chain could delay product availability and impact revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Ulixacaltamide: The company has completed the NDA submission for ulixacaltamide for essential tremor and expects approval in the near future. Preparations for commercial launch are underway, targeting an addressable population of 2 million in the U.S. with a potential annual revenue of over $10 billion. A comprehensive medical education campaign is planned for launch at the American Academy of Neurology Annual Meeting in April.
Relutrigine: The NDA for relutrigine in SCN2A and 8A DEEs has been submitted, with approval expected to enable participation in the pediatric review voucher program. The EMBOLD study for broader DEE population is on track for completion this year, with a supplemental NDA expected by 2027. The potential annual revenue for relutrigine in DEE space is estimated at $5 billion. Prelaunch activities and inventory preparations are ongoing.
Vormatrigine: Multiple readouts from pivotal studies are expected in the next 12-18 months. Top-line results for the POWER1 study in focal onset seizures are anticipated in Q2 2026, with POWER2 enrollment completion expected by year-end. The POWER3 study will initiate in the first half of 2026. Vormatrigine has the potential to address unmet needs of 3 million people in the U.S. with common epilepsies, with an estimated annual revenue of $4 billion.
Elsunersen: The EMBRAVE3 trial design has been updated, and enrollment is expected to complete this year, with a potential NDA submission in 2027. Top-line results from the EMBRAVE study Part A are expected in the first half of 2026. Elsunersen has rare pediatric drug designation and potential annual revenue of over $1 billion.
Financial Outlook: The company expects a significant increase in spending in 2026 for commercial launch activities and pipeline progression. With a pro forma cash position of approximately $1.5 billion, operations are funded into 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you walk us through the pre-commercial activities for ulixacaltamide and relutrigine and their cadence through 2026?
A:The company is making key hires to build out the commercial organization, ensuring sufficient inventory for strong launches, and improving disease awareness for ulixacaltamide. They are also preparing for presentations at the American Academy of Neurology (AAN) meeting to share clinical data and expand understanding among neurologists.
Q:What additional new data can we expect at the AAN meeting?
A:There will be about 15 presentations, including oral presentations on clinical data for the Essential3 program and essential tremor. These presentations will provide detailed insights into the clinical program, including the primary measure mADL11 and other endpoints, aimed at neurologists.
Q:What is the status of alternative titration schedules for ulixacaltamide, and are additional studies being conducted to support this?
A:The company has proposed an alternative titration schedule to the FDA, which involves staying at 20 mg for longer. The FDA has indicated that no pre-approval clinical studies are required for this, as it is not a safety issue but rather a tolerability matter for a subset of patients.
Q:How is capital being allocated between the commercial preparations for ulixacaltamide and relutrigine?
A:More capital is being allocated to ulixacaltamide due to its broader market, including a larger field force, disease awareness campaigns, and inventory build. Relutrigine's efforts are more focused, targeting specific physician groups and laying groundwork for future indication expansion.
Q:How will the POWER3 study help move vormatrigine towards the frontline setting?
A:POWER3 aims to address the broader market of patients with focal onset seizures who are not hyper-refractory. The study is designed to build confidence among physicians for using vormatrigine as a first-line treatment, although it is not required for registration.
Q:What is the review timeline for the NDAs, and will there be priority reviews?
A:The company has requested a priority review for relutrigine but not for ulixacaltamide. The decision for ulixacaltamide was influenced by strategic business considerations, including launch timing and payer dynamics.
Q:Why did the company decide against requesting a priority review for ulixacaltamide?
A:The decision was influenced by strategic business reasons, including the timing of the launch and the impact of the Inflation Reduction Act on Medicare Part D populations. A standard review aligns better with long-term revenue maximization.
Q:Can we expect long-term follow-up data for ulixacaltamide at the AAN meeting?
A:Yes, the company plans to present data that reinforces both short-term and long-term efficacy, focusing on the depth of effect and the proportion of patients benefiting from the treatment.
Q:What is the pricing strategy for ulixacaltamide?
A:The company has previously indicated a list price of around $50,000 and is considering payer dynamics, reauthorization processes, and the Inflation Reduction Act in its pricing strategy.
Q:How many different DEE patients are being enrolled in the EMERALD study, and what are the expectations for efficacy?
A:The study includes a diverse group of patients with developmental epileptic encephalopathies (DEE), focusing on phenotypically defined patients. Preclinical data suggests strong efficacy, and the company expects similar or better results compared to SCN2A and SCN8A indications.
Q:Will relutrigine be used across the entire spectrum of DEEs, including indications with ASOs or targeted therapies?
A:Yes, relutrigine is expected to be used broadly, including in combination with ASOs, as it addresses a fundamental mechanism in seizures. It is seen as a complementary therapy rather than a silver bullet.
Q:Are patients in the RADIANT study withdrawing from background medications while on vormatrigine?
A:Yes, patients are reducing or eliminating background medications while maintaining seizure control, which highlights vormatrigine's efficacy and safety profile.
Q:What are the expectations for the EMBRAVE study for elsunersen?
A:The EMBRAVE study aims to provide controlled data on safety, efficacy, and pharmacokinetics. The FDA has allowed a single-arm design for EMBRAVE3, which is expected to complete this year, potentially leading to another NDA submission.
Q:What are the plans for ulixacaltamide outside the U.S.?
A:The company is currently focused on the U.S. market and ensuring a high-quality launch. While there is unmet need outside the U.S., international efforts are not a priority at this time.
Q:What is the potential for synergies between the launches of ulixacaltamide and relutrigine?
A:While there is overlap in prescriber populations, the company is taking separate go-to-market strategies for each drug to maximize their individual launches. Future launches may leverage these synergies more effectively.
Q:How does the company view the FDA's position on one adequate and well-controlled study for marketing authorization?
A:The company supports the FDA's evolving stance and believes it could benefit future drug development, but it is not relying on this for its current programs.
Q:What is the status of the essential tremor patient database?
A:The database is well-developed and validated, with a detailed understanding of prescriber patterns. More updates will be provided during the company's Commercial Day.
Q:How does vormatrigine fit into the evolving landscape of focal epilepsy treatments?
A:Vormatrigine is positioned as a potential first-line treatment, differentiating itself from potassium channel-focused therapies that target refractory patients.
Q:What is the status of the alternative titration protocol for ulixacaltamide?
A:The alternative protocol involves staying at 20 mg for longer to improve tolerability. The FDA has not required additional pre-approval studies for this adjustment.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the potential for priority review for ulixacaltamide, providing only strategic business reasons without detailed specifics. Additionally, they did not provide clear updates on the essential tremor patient database, deferring this to a future Commercial Day.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
American
Annual Meeting
FDA NDA
III study
Medicines Full
NDA submission
Phase III
RD GA
SCNA DEEs
core
designation review
disease potential
drug designation
effort
elsunersen EMBRAVE
hire
increase spend
launch relutrigine
line result
meeting FDA
people United
portfolio
prelaunch
proceeds
program vormatrigine
relutrigine DEE
relutrigine SCNA
result program
sham
study NDA
study vormatrigine
tremor
PRAX Transcript
Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call summary presents a mixed outlook. Financial performance and product development updates appear positive, with new studies and strategic pricing strategies. However, management's vague responses in the Q&A raise concerns about transparency, particularly regarding ulixacaltamide's review process and essential tremor database updates. This lack of clarity may offset the positives, leading to a neutral sentiment.
Praxis Precision Medicines, Inc. (PRAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-21
Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call highlights strong clinical trial results for vormatrigine, with impressive seizure reduction rates and a solid safety profile. The company has a cash runway until 2028, supporting its clinical agenda. Although there are execution risks with new studies, the positive outcomes from the RADIANT study and the strategic move towards monotherapy indicate potential for growth. The Q&A section reveals robust efficacy across different therapies and a positive outlook for ongoing studies, reinforcing a positive sentiment despite some operational risks.
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Unknown11-6
The earnings call highlights a strong cash position and funding runway, but lacks immediate catalysts like new partnerships or record revenues. While there are clinical advancements, regulatory and clinical trial risks could offset potential gains. The Q&A reveals some uncertainties, such as interim analysis timing and patient enrollment updates, which may concern investors. Given these factors, the stock is likely to remain stable in the short term.
PRAX Slides
PRAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
